ClinicalTrials.gov
ClinicalTrials.gov Menu

Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study (CTS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01476943
Recruitment Status : Active, not recruiting
First Posted : November 22, 2011
Last Update Posted : January 12, 2018
Sponsor:
Collaborator:
Heidelberg University
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The primary purpose is to describe the pattern of Belatacept use at the time of transplant and up to three years post-transplantation for all Belatacept treated patients.

Condition or disease
Transplantation, Organ

Detailed Description:
Time Perspective: Prospective design, Retrospective data collection and analysis

Study Type : Observational
Estimated Enrollment : 4335 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Belatacept in Renal Transplantation: Patterns of Use Analysis Using the Collaborative Transplant Study (CTS)
Actual Study Start Date : March 31, 2012
Estimated Primary Completion Date : April 30, 2018
Estimated Study Completion Date : April 30, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Belatacept
U.S. FDA Resources

Group/Cohort
Patient treated with Belatacept at the time of transplantation
Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
Patient treated with CNI at the time of transplantation
Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation



Primary Outcome Measures :
  1. The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by Cytomegalovirus (CMV) serostatus [ Time Frame: At the time of transplantation ]
  2. The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus [ Time Frame: 1 year post transplantation ]
  3. The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus [ Time Frame: 2 year post transplantation ]
  4. The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus [ Time Frame: 3 year post transplantation ]

Secondary Outcome Measures :
  1. Extent of switches to or from Belatacept within three years post transplantation, and the temporal trend in switches post regulatory approval of Belatacept [ Time Frame: At transplantation, 12 month, 24 month and 36 month post transplantation ]
  2. Characteristics of Belatacept users vs. Calcineurin inhibitor (CNIs) users at transplantation [ Time Frame: At the time of transplantation ]
  3. Characteristics of those who switch to or from Belatacept vs. those who do not switch one year post-transplant [ Time Frame: At transplantation and 12 month post transplantation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept or a CNI based regimen at the time of transplantation
Criteria

Inclusion Criteria:

  • Patients who received solid organ transplantation during study period in one of the transplant centers involved in CTS

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01476943


Sponsors and Collaborators
Bristol-Myers Squibb
Heidelberg University
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01476943     History of Changes
Other Study ID Numbers: IM103-077
First Posted: November 22, 2011    Key Record Dates
Last Update Posted: January 12, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Abatacept
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents